Head-To-Head Review: Q32 Bio (QTTB) versus Its Competitors

Q32 Bio (NASDAQ:QTTB – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Q32 Bio to similar businesses based on the strength of its dividends, profitability, analyst recommendations, earnings, institutional ownership, valuation and risk.

Insider & Institutional Ownership

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Q32 Bio and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Q32 Bio N/A 17.03% 15.24%
Q32 Bio Competitors -12,224.09% -202.33% -31.23%

Volatility & Risk

Q32 Bio has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Q32 Bio’s competitors have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Q32 Bio and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Q32 Bio 1 1 6 1 2.78
Q32 Bio Competitors 9919 15313 45656 1602 2.54

Q32 Bio presently has a consensus price target of $32.17, suggesting a potential upside of 269.31%. As a group, “Biotechnology” companies have a potential upside of 126.17%. Given Q32 Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Q32 Bio is more favorable than its competitors.

Earnings and Valuation

This table compares Q32 Bio and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Q32 Bio $53.74 million $29.82 million 2.61
Q32 Bio Competitors $720.07 million $10.07 million -18.81

Q32 Bio’s competitors have higher revenue, but lower earnings than Q32 Bio. Q32 Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Q32 Bio beats its competitors on 11 of the 13 factors compared.

About Q32 Bio

(Get Free Report)

Q32 Bio is a biotechnology company focused on developing treatments for autoimmune and inflammatory diseases by targeting pathways that regulate the immune system. Its research has centered on biologic medicines designed to restore immune balance and address disease mechanisms. The company’s programs have included ADX-097, a complement C3 inhibitor designed to target activity in affected tissues, and ADX-914, an antibody targeting the interleukin-7 receptor alpha. Q32 Bio has been based in the United States and has advanced its programs through clinical development.

Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.